NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

There are currently no pharmaceutical treatments approved for general obesity in under-12s — as opposed to that found with some rare genetic disorders — said Claudia Fox, a professor from University ...

In 2023, Norditropin, manufactured by Novo Nordisk, led the growth hormone deficiency market with revenue of USD 1.6 billion, maintaining a significant market share. Norditropin is anticipated to ...

The drug manufacturer has developed a pill that could bring about weight loss of as much as 13% in three months, according to ...

The pill isn’t Ozempic—it’s called Amycretin—but like that drug it mimics the GLP-1 hormone ... Novo Nordisk to a $500 billion valuation. The company is expecting profit growth of 29% ...

Overall, recent studies have shown that GLP-1 drugs have led to a 10-20% reduction in body weight and lowered the risk of heart attack, stroke and cardiovascular death by approximately 20%.

One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...

Interview with the Milanese immunologist Attilio Speciani. They call it an anti-obesity drug, but it's not just that: in ...